• In late May 2026, The Clorox Company announced that Chair and CEO Linda Rendle will step down for health reasons, with a comprehensive board-led search underway while she remains in place and then transitions to an advisory role to support continuity.
• This planned leadership change comes as Clorox is working through operational and demand challenges, making succession decisions particularly important for the company’s direction.
• We’ll examine how Rendle’s planned departure and the board’s CEO search process could shape Clorox’s existing investment narrative and risk profile.

The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

Clorox Investment Narrative Recap

To own Clorox, you need to believe its brands and ongoing ERP and digital investments can translate into steadier earnings, even as sales and free cash flow have recently come under pressure. The planned CEO transition adds headline uncertainty, but with a board led search and Rendle staying through the handover, the most immediate catalyst remains the company’s ability to stabilize demand and margins, while the biggest near term risk is that competitive and pricing pressures keep eroding profitability.

The recent launch of Clorox Healthcare Quat Alcohol and HyperOxi disinfecting wipes shows the pipeline of new products that could support the innovation driven catalyst many investors are watching. These offerings tie directly into the thesis that differentiated formulations in health and hygiene can help Clorox defend share and pricing, which matters all the more as the company works through leadership change and softer category trends.

Yet behind the familiar brands, one risk investors should be aware of is how intensifying private label competition could...

Clorox's narrative projects $7.9 billion revenue and $911.5 million earnings by 2029. This requires 5.2% yearly revenue growth and about a $156.5 million earnings increase from $755.0 million today.

Uncover how Clorox's forecasts yield a $115.47 fair value, a 29% upside to its current price.

Exploring Other Perspectives

Some of the lowest estimate analysts already saw slower profit recovery, with earnings only reaching about US$778.6 million by 2029, and they pair that with concerns about heavier competition from private labels and online native brands. Taken together with the CEO transition, their view represents a materially more pessimistic scenario than the baseline and it is exactly the kind of alternative outlook you may want to weigh against your own expectations.

Explore 7 other fair value estimates on Clorox - why the stock might be worth as much as 90% more than the current price!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Clorox research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Clorox research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Clorox's overall financial health at a glance.

Want Some Alternatives?

Every day counts. These free picks are already gaining attention. See them before the crowd does:

• We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Explore 30 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.